# Sisyphus

**Graph-based whole-body PBPK simulation with native uncertainty propagation**

[Methodology](#methodology) &middot; [Quickstart](#quickstart) &middot; [Validation](#validation) &middot; [Architecture](#architecture) &middot; [Limitations](#limitations)

---

Sisyphus is a physiologically based pharmacokinetic (PBPK) platform that represents the human body as a typed directed multi-graph, derives ordinary differential equation (ODE) systems from graph topology, and propagates parameter uncertainty natively through Monte Carlo sampling.

The platform accepts a SMILES string and dosing regimen as input and produces PK endpoints (C<sub>max</sub>, T<sub>max</sub>, AUC, t<sub>1/2</sub>) with 90% prediction intervals. Beyond single-dose prediction, Sisyphus supports multi-dose regimen simulation with steady-state detection, Bayesian therapeutic drug monitoring (TDM) via importance sampling, model-informed precision dosing (MIPD), drug-drug interaction (DDI) modeling, and PK/PD effect estimation.

```
$ sisyphus predict --smiles "Cn1c(=O)c2c(ncn2C)n(C)c1=O" --dose 100

Drug: Cn1c(=O)c2c(ncn2C)n(C)c1=O
Method: hybrid
Confidence: high
Cmax: 1.5247 mg/L
Tmax: 0.96 h
t½: 4.32 h
```

## Methodology

### Physiological model

The body is represented as a 34-compartment directed multi-graph comprising blood pools (arterial, venous, portal vein), perfusion-limited organs (11), permeability-limited organs (4, each split into vascular and extravascular sub-compartments), GI lumen segments (8, compartmental absorption and transit model; Yu &amp; Amidon, 1999), and mass-balance sinks (4). Physiological parameters follow the ICRP Reference Man (ICRP, 2002). Tissue compositions for partition coefficient estimation are taken from Rodgers &amp; Rowland (2005). CYP enzyme abundances follow Shimada et al. (1994).

```
                      ┌─────────────────────────────────────────────┐
                      │                                             │
   ┌──────┐    ┌──────┴───┐                                   ┌─────┴────┐
   │ lung │───►│ arterial │─► brain ─────────────────────────►│ venous   │
   └──┬───┘    │  blood   │─► heart ─────────────────────────►│  blood   │
      │        │          │─► kidney ────────────────────────►│          │
      │        │          │                                   │          │
      │        │          │─► gut wall ──┐                    │          │
      │        │          │─► spleen  ───┤ portal ► liver ───►│          │
      │        │          │─► pancreas ──┘  vein   (CYP450)   │          │
      │        │          │                                   │          │
      │        │          │─► muscle, adipose, skin, bone ───►│          │
      │        └──────────┘                                   └─────┬────┘
      │                                                             │
      └─────────────────────────────────────────────────────────────┘

   stomach ──► duodenum ──► jejunum ──► ileum ──► colon ──► fecal excretion
                  │            │          │
                  └────────────┴──────────┘
                       absorption ──► gut wall
```

### ODE formulation

The ODE system is derived automatically from graph topology. Each edge type dispatches a flux function:

**Perfusion-limited transport** (FlowFluxSpec):

$$\frac{dA_i}{dt} = Q_i \cdot C_{in} - Q_i \cdot \frac{A_i \cdot R_{B:P}}{V_i \cdot K_{p,i}}$$

**Well-stirred hepatic clearance** (ClearanceFluxSpec):

$$CL_{int,organ} = \sum_j \left( E_j \cdot k_j \right) \cdot S_{IVIVE}$$

$$CL_{organ} = \frac{Q \cdot f_u \cdot CL_{int,organ}}{Q + f_u \cdot CL_{int,organ}}$$

where $E_j$ is the enzyme abundance (total pmol in organ), $k_j$ is the per-enzyme intrinsic clearance (&mu;L/min/pmol), and $S_{IVIVE}$ converts units (60/10<sup>6</sup>, &mu;L/min &rarr; L/h). This formulation is **enzyme-level**: clearance at any organ is computed from its local enzyme profile, not from organ identity (Houston, 1994; Yang et al., 2007).

**Permeability-limited distribution** (DiffusionFluxSpec):

$$\frac{dA_{vasc}}{dt} = Q \cdot C_{art} - Q \cdot C_{vasc} - PS \cdot (C_{u,vasc} - C_{u,tissue})$$

$$\frac{dA_{tissue}}{dt} = PS \cdot (C_{u,vasc} - C_{u,tissue})$$

**GI absorption** (AbsorptionFluxSpec):

$$k_a = \frac{2.88 \cdot P_{eff} \cdot f_{ka}}{r}$$

where $P_{eff}$ is effective permeability (&times;10<sup>&minus;4</sup> cm/s), $f_{ka}$ is the segment-specific absorption fraction, and $r$ is particle radius (&mu;m).

**Tissue:plasma partition coefficients** are computed via the Rodgers &amp; Rowland method (Rodgers &amp; Rowland, 2005, 2006), with the Berezhkovskiy correction for acids (Berezhkovskiy, 2004).

### Prediction pipeline

The full pipeline combines mechanistic simulation with data-driven prediction:

1. **SMILES &rarr; molecular profile**: RDKit descriptors, structural pK<sub>a</sub> classification, applicability domain assessment
2. **ADME prediction**: Pre-trained XGBoost models for f<sub>u,p</sub>, CL<sub>int</sub>, R<sub>B:P</sub>, VD<sub>ss</sub> (trained on TDC datasets; Huang et al., 2021)
3. **IVIVE**: CL<sub>int</sub> decomposition into per-enzyme affinities, Kp calculation
4. **PBPK simulation**: 34-state ODE system solved via LSODA (Petzold, 1983)
5. **ML direct prediction**: XGBoost C<sub>max</sub> model (trained on 1,128 drugs)
6. **Meta-learner**: Calibrated geometric combination of PBPK and ML C<sub>max</sub> (engine weight 0.17, ML weight 0.83)

### Uncertainty propagation

All parameters are represented as `Distribution(mean, cv, dist_type)`. Monte Carlo sampling draws N realizations from all parameter distributions simultaneously, solves the ODE for each, and aggregates the resulting PK endpoints into distributional summaries with prediction intervals. The graph topology is compiled once; only parameter values change across MC iterations ("compile once, parameterize many").

### Multi-dose regimen simulation

Multi-dose pharmacokinetics are computed by an event-driven solver that wraps the single-dose ODE engine. Dose events are injected into the state vector between integration segments; the ODE right-hand side is not modified. This preserves the identity-blind engine invariant while supporting arbitrary dosing schedules (repeated oral, IV infusion, mixed regimens).

Steady-state detection applies a trough variation criterion (&lt;5%) across the last three dosing intervals. The solver reports C<sub>ss,max</sub>, C<sub>ss,min</sub>, accumulation ratio (AR = C<sub>ss,max</sub> / C<sub>max,first</sub>), and dose number at which steady state is reached.

### Therapeutic drug monitoring

Given observed plasma concentrations from a patient, Sisyphus refines population-level parameter distributions into individual posteriors via importance sampling:

1. Draw $N$ samples from prior parameter distributions (physiology and drug).
2. For each sample, simulate the administered regimen and interpolate predicted concentration at each observation time.
3. Compute per-sample likelihood assuming normally distributed assay error: $L_i = \prod_k \phi\left(C_{obs,k} \mid C_{pred,k}^{(i)},\ \sigma_{assay}\right)$
4. Importance weights $w_i \propto L_i$, normalized so $\sum w_i = 1$.
5. Effective sample size $ESS = 1 / \sum w_i^2$ monitors weight degeneracy.
6. Weighted statistics yield posterior distributions for all PK parameters.

This mechanism bypasses the CL<sub>int</sub> prediction ceiling (R&sup2; &asymp; 0.24): observed drug levels directly correct inaccurate population priors, reducing posterior CV by &gt;50% in validation (see [TDM validation](#tdm-validation)).

### Model-informed precision dosing

MIPD recommends adjusted doses to achieve a target steady-state concentration:

1. Bayesian update at the observed dose yields a posterior C<sub>ss</sub> distribution.
2. Linear dose scaling: $dose_{new} = dose_{current} \times (C_{ss,target} / C_{ss,posterior})$
3. Clamp to clinical dose range and round to a practical increment (default 25 mg).

Linear scaling assumes non-saturable metabolism, which holds for most drugs at therapeutic concentrations. For drugs with known nonlinear pharmacokinetics (e.g., phenytoin), this approximation should be used with caution.

### Drug-drug interactions

DDI is modeled by adjusting enzyme abundances in the body graph prior to ODE compilation. The engine sees modified abundances and computes clearance as usual &mdash; no engine modifications are required.

**Competitive inhibition:**

$$E_{eff} = \frac{E_{base}}{1 + [I] / K_i}$$

**Enzyme induction (E<sub>max</sub> model):**

$$E_{eff} = E_{base} \cdot \left(1 + \frac{E_{max} \cdot [I]}{EC_{50} + [I]}\right)$$

where $E_{base}$ is baseline enzyme abundance (pmol), $[I]$ is perpetrator plasma concentration, $K_i$ is the inhibition constant, and $E_{max}$/$EC_{50}$ are induction parameters. Preset perpetrators: ketoconazole, fluconazole, quinidine (CYP inhibitors) and rifampin (CYP3A4 inducer).

### PK/PD link

Pharmacodynamic effects are computed from the concentration-time profile via an effect compartment with sigmoid E<sub>max</sub> response:

**Effect-site equilibration:**

$$\frac{dC_e}{dt} = k_{e0} \cdot (C_p - C_e)$$

**Sigmoid E<sub>max</sub> response:**

$$E = E_0 + \frac{E_{max} \cdot C_e^n}{EC_{50}^n + C_e^n}$$

where $k_{e0}$ is the effect-site equilibration rate constant (h<sup>&minus;1</sup>), $E_0$ is the baseline effect, and $n$ is the Hill coefficient. This is implemented as analytical post-processing on the PK solution, not as additional ODE states, preserving engine isolation. Preset PD models are provided for midazolam (sedation) and warfarin (INR response).

## Quickstart

### Installation

```bash
pip install -e ".[dev,ml,chem]"
```

> Pre-trained XGBoost models (f<sub>u,p</sub>, CL<sub>int</sub>, C<sub>max</sub>, meta-learner) are required in `models/`. These are not tracked in git due to size. They originate from the [Omega PBPK](https://github.com/jam-sudo/Omega) predecessor project.

### CLI

Six commands cover the clinical pharmacology workflow:

```bash
# Single-dose PK prediction
sisyphus predict --smiles "Cn1c(=O)c2c(ncn2C)n(C)c1=O" --dose 100

# Multi-dose regimen simulation (atorvastatin 40 mg QD × 14 days)
sisyphus simulate --smiles "CC(C)c1n(CC(O)CC(O)CC(=O)O)c(=O)..." \
    --dose 40 --interval 24 --doses 14

# TDM Bayesian update (midazolam 5 mg, observed 0.015 mg/L at t=1 h)
sisyphus tdm --smiles "c1ccc2c(c1)C(=NC(=O)N2)c1ccccc1F" \
    --dose 5 --obs "1.0:0.015"

# DDI prediction (midazolam + ketoconazole inhibition)
sisyphus ddi --smiles "c1ccc2c(c1)C(=NC(=O)N2)c1ccccc1F" \
    --dose 5 --inhibitor ketoconazole

# MIPD dose recommendation (target Css,max = 0.02 mg/L)
sisyphus dose-adjust --smiles "c1ccc2c(c1)C(=NC(=O)N2)c1ccccc1F" \
    --dose 5 --obs "1.0:0.015" --target-css 0.02

# Holdout benchmark
sisyphus benchmark --holdout
```

All commands accept `--verbose` for debug-level logging.

### Python API

```python
from sisyphus.pipeline.predict import predict

result = predict("Cn1c(=O)c2c(ncn2C)n(C)c1=O", dose_mg=100.0)

print(result.pk.cmax.mean)    # 1.52 mg/L
print(result.method)          # "hybrid"
print(result.confidence)      # "high"
```

### Engine-only mode (known compound parameters)

For validation or mechanistic studies, the engine can be driven directly from compound YAML files, bypassing ADME prediction:

```python
from pathlib import Path
import numpy as np
from sisyphus.graph.builder import build_from_yaml
from sisyphus.compounds import load_compound
from sisyphus.engine.compiler import ODECompiler, ResolvedParams
from sisyphus.engine.solver import solve
from sisyphus.pk.endpoints import compute_endpoints
import sisyphus.engine.flux  # register flux functions

graph = build_from_yaml(Path("data/physiology/reference_man.yaml"))
drug = load_compound(Path("data/compounds/midazolam.yaml"))

compiled = ODECompiler().compile(graph)
rng = np.random.default_rng(42)
params = ResolvedParams(graph.sample(rng), drug.sample(rng))

y0 = np.zeros(compiled.n_states)
y0[compiled.state_index[drug.administration_node]] = drug.dose_mg

result = solve(compiled, params, y0, t_span=(0, 24))
pk = compute_endpoints(result)

print(f"Cmax: {pk.cmax.mean:.4f} mg/L")  # 0.0069 mg/L (matches Omega ±0.5%)
```

### Monte Carlo uncertainty

```python
from sisyphus.engine.uncertainty import UncertaintyEngine

ue = UncertaintyEngine()
mc = ue.propagate_fast(compiled, graph, drug, n_samples=1000)

print(mc.pk.cmax)                # Distribution(mean=1.76, cv=0.19)
print(mc.cmax_90ci)              # (1.28, 2.35) mg/L
print(len(mc.cmax_samples))      # 1000 individual realizations
```

## Validation

### Engine validation against Omega PBPK

Four drugs with known compound parameters were simulated and compared against the [Omega PBPK](https://github.com/jam-sudo/Omega) ODE engine (35-state hardcoded model):

| Drug | Dose | Sisyphus C<sub>max</sub> (mg/L) | Omega C<sub>max</sub> (mg/L) | Relative error |
|------|:----:|:------------:|:----------:|:-----:|
| Midazolam | 2 mg PO | 0.006911 | 0.006943 | 0.5% |
| Caffeine | 100 mg PO | 1.7151 | 1.7139 | 0.1% |
| Warfarin | 10 mg PO | 0.4917 | 0.4922 | 0.1% |
| Propranolol | 80 mg PO | 0.1353 | 0.1355 | 0.1% |

Mass balance error &lt; 10<sup>&minus;12</sup> for all simulations.

### Holdout benchmark (SMILES &rarr; C<sub>max</sub>)

External validation on a Murcko scaffold-stratified holdout set (seed=42, never used in training or model selection). Performance is reported using AAFE (Absolute Average Fold Error; Obach et al., 1997):

$$AAFE = 10^{\operatorname{mean}\left(\left|\log_{10}\frac{C_{max,pred}}{C_{max,obs}}\right|\right)}$$

| Metric | Value | N |
|--------|:-----:|:---:|
| Holdout AAFE (meta-learner) | **2.058** | 61 |
| Holdout %2-fold | **55.7%** | 61 |
| Engine-only AAFE | 2.945 | 61 |

The meta-learner combines mechanistic PBPK simulation (weight 0.17) with data-driven XGBoost C<sub>max</sub> prediction (weight 0.83) via LOOCV-calibrated geometric weighting, validated on all 61 holdout drugs.

**Note on validation size.** The holdout set (N=61) is small relative to chemical space. Confidence intervals on the AAFE are not reported. A larger reference dataset with multi-source clinical PK data would strengthen validation.

### Multi-dose regimen validation

Three drugs were simulated at clinical dosing regimens and compared against FDA-label steady-state C<sub>max</sub> values:

| Drug | Regimen | Predicted C<sub>ss,max</sub> (mg/L) | FDA label C<sub>ss,max</sub> (mg/L) | Fold error |
|------|---------|:---:|:---:|:---:|
| Atorvastatin | 40 mg QD | 0.027 | 0.029 | 0.93 |
| Metformin | 500 mg BID | 0.55 | 1.0 | 0.55 |
| Warfarin | 5 mg QD | 0.34 | 1.4 | 0.24 |

Atorvastatin (CYP3A4-mediated, moderate protein binding) was predicted within 7% of the label value. Metformin (renal elimination-dominant, f<sub>u</sub> &asymp; 1.0) and warfarin (f<sub>u</sub> = 0.01, highly protein-bound) show expected under-prediction consistent with the model&rsquo;s known limitations in renal clearance modeling and CL<sub>int</sub> over-prediction for highly bound compounds. Accumulation ratio direction was correct for all three drugs. Steady-state detection operated correctly in all cases.

### TDM validation

Bayesian update was validated using midazolam (5 mg single oral dose, one observed concentration at t = 1 h with 10% assay noise):

| Metric | Prior | Posterior |
|--------|:-----:|:---------:|
| C<sub>max</sub> CV | 44.3% | 19.8% |
| ESS | &mdash; | 586.6 (29.3% of 2,000) |
| CV reduction | &mdash; | 55.4% |

The posterior CV (19.8%) is less than half the prior CV (44.3%), demonstrating that a single noisy observation substantially refines parameter estimates. ESS of 586.6 (29.3% of prior samples) indicates adequate weight distribution without degeneracy.

### Performance

| Operation | Time | Configuration |
|-----------|:----:|------|
| Full prediction (SMILES &rarr; C<sub>max</sub>) | 414 ms | Deterministic, single core |
| ODE solve (full fidelity) | 106 ms | LSODA, rtol=10<sup>&minus;8</sup>, atol=10<sup>&minus;10</sup> |
| ODE solve (MC fast path) | 33 ms | LSODA, rtol=10<sup>&minus;4</sup>, atol=10<sup>&minus;6</sup> |
| MC N=1,000 | 33.5 s | Pure Python RHS (no JIT compilation) |
| RHS evaluation | 31 &mu;s | 54 flux specs per call |

Single-patient deterministic prediction completes in &lt;500 ms, compatible with interactive clinical decision support workflows. MC propagation at N=1,000 requires ~34 s due to pure Python ODE evaluation; JIT compilation (e.g., via Numba) is an optimization path not yet pursued.

## Architecture

```
SMILES + dose
    │
    ▼
 predict ──► DrugOnGraph (enzyme-level, all values are Distribution)
                  │
                  ▼
             engine ◄── BodyGraph (from YAML)
             (compile graph → ODE → solve → MC propagate)
                  │
                  ▼
               pk (Cmax, AUC, t½ from SimResult)
                  │
    ml ───────────┤
    (direct PK)   │
                  ▼
             pipeline (meta-learner → final PredictionResult)
                  │
       ┌──────────┼──────────┐
       ▼          ▼          ▼
    regimen      ddi       pkpd
   (multi-dose, (enzyme    (effect
    TDM, MIPD)  adj.)     compartment)
```

| Layer | Responsibility | Depends on |
|-------|---------------|------------|
| `graph/` | BodyGraph, node/edge types, YAML builder | `core` |
| `engine/` | ODE compiler, flux registry, solver, MC | `core`, `graph` |
| `predict/` | SMILES &rarr; chemistry &rarr; ADME &rarr; DrugOnGraph | `core` |
| `ml/` | XGBoost C<sub>max</sub>, meta-learner | `core` |
| `pk/` | SimResult &rarr; PKEndpoints | `core` |
| `regimen/` | Multi-dose solver, TDM Bayesian update, MIPD | `core`, `engine`, `graph` |
| `pipeline/` | Orchestrator wiring all layers | all layers |
| `ddi.py` | Drug-drug interactions (competitive inhibition, E<sub>max</sub> induction) | `core`, `graph` |
| `pkpd.py` | PK/PD effect modeling (effect compartment, sigmoid E<sub>max</sub>) | `core` |

**Layer isolation.** No cross-layer imports outside designated dependencies. `predict` does not import `engine`. `engine` does not import `predict`. `regimen` wraps `engine` without modifying it. Shared data types live in `core.py`.

### Design principles

1. **Identity-blind engine.** The ODE compiler and flux functions operate on node/edge *types*, never on *identities*. No string matching on organ names, enzyme names, or drug names exists in `engine/`. Replacing all organ names with random strings produces identical numerical results.

2. **Distribution-native.** All physiological and drug parameters are `Distribution` objects. Point estimates are represented as `Distribution(mean=x, cv=0)`. The uncertainty system is not an add-on; it is the system&rsquo;s native representation.

3. **Compile once, parameterize many.** Graph topology is compiled into an ODE skeleton once. MC iterations change only parameter values, not structure. 1,000 MC samples = 1 compilation + 1,000 ODE solves.

## Extending the Model

The architecture is designed so that new compartments, routes, populations, interaction models, and clinical workflows require **zero changes to the ODE engine**. This was validated empirically: subcutaneous injection, pediatric physiology, tumor compartment, DDI, PK/PD, multi-dose regimen, and TDM were each implemented with 0 lines changed in `src/sisyphus/engine/`.

### New organ (tumor compartment)

```yaml
nodes:
  - name: tumor
    type: organ
    volume: 0.05
    composition: {fn: 0.013, fp: 0.010, fw: 0.700, pH: 6.8}
edges:
  - {source: arterial_blood, target: tumor, type: flow, flow_fraction: 0.005}
  - {source: tumor, target: venous_blood, type: flow}
```

### New route (subcutaneous injection)

```python
graph.add_node(Node(name="sc_depot", node_type="lumen", volume=Distribution(0.01)))
graph.add_edge(AbsorptionEdge(source="sc_depot", target="venous_blood",
                               ka_fraction=Distribution(1.0)))
```

### New population (pediatric)

Allometrically scaled physiology (cardiac output &prop; BW<sup>0.75</sup>) with ontogeny-adjusted enzyme abundances (e.g., CYP3A4 at 50% of adult at age 5). Same graph structure, different YAML parameters.

### Drug-drug interactions

Competitive CYP inhibition via pre-simulation enzyme abundance adjustment:

```python
from sisyphus.ddi import apply_inhibition, KETOCONAZOLE

inhibited_graph = apply_inhibition(graph, KETOCONAZOLE)
# Midazolam AUC increases 12x (clinical reference: ~15x)
```

### PK/PD modeling

Effect compartment with sigmoid E<sub>max</sub> response, computed as post-processing on the concentration-time profile:

```python
from sisyphus.pkpd import compute_effect, PDModel

pd = PDModel(ke0=0.5, emax=100.0, ec50=0.05, hill=2.0)
effect = compute_effect(sim_result, pd)
```

## Limitations

- **Small-molecule oral PK only.** Biologics (antibodies, ADCs), parenteral formulations beyond SC, and non-oral routes (inhalation, topical) are not validated.
- **No prodrug metabolism.** C<sub>max</sub> is predicted for the parent compound. Prodrugs (e.g., valacyclovir, fesoterodine) are flagged as out-of-applicability-domain.
- **Simplified pK<sub>a</sub>.** Ionization state is classified by structural rules (carboxylic acid &rarr; 4.5, aliphatic amine &rarr; 9.0), not computed quantum-mechanically. This limits Kp accuracy for highly ionized compounds.
- **No Phase II metabolism.** Glucuronidation (UGT), sulfation (SULT), and acetylation (NAT2) are not modeled. Drugs primarily cleared by conjugation will be under-predicted.
- **No transporter-mediated disposition in ODE.** P-gp efflux is handled via a binary permeability correction, not as a mechanistic transport term in the ODE.
- **CL<sub>int</sub> prediction is the weakest link.** The XGBoost CL<sub>int</sub> model achieves R&sup2; &asymp; 0.24 on TDC Hepatocyte_AZ. This is the single largest source of prediction error. Bayesian TDM partially mitigates this: observed drug levels correct inaccurate population priors, reducing prediction CV by &gt;50% (see [TDM validation](#tdm-validation)).
- **R<sub>B:P</sub> defaults to 1.0.** The RBP model (R&sup2; = &minus;0.08 on external data) is effectively disabled; all drugs are assumed to have equal blood and plasma concentrations.
- **MIPD assumes linear pharmacokinetics.** Dose recommendations use linear scaling, which may be inaccurate for drugs with saturable metabolism (e.g., phenytoin) or nonlinear protein binding.
- **Small validation set.** The holdout set (N=61) is small relative to chemical space. Confidence intervals on the AAFE are not reported. A larger reference dataset with multi-source clinical PK data would strengthen validation.

## Project Structure

```
src/sisyphus/
├── core.py              # Distribution, TissueComposition, data contracts
├── descriptors.py       # Morgan fingerprints + RDKit descriptors
├── compounds.py         # Compound YAML → DrugOnGraph loader
├── ddi.py               # Drug-drug interaction modeling
├── pkpd.py              # PK/PD effect compartment + Emax
├── cli.py               # Command-line interface (6 commands)
│
├── graph/               # Body graph definition and construction
│   ├── types.py         # Node, Edge type hierarchy (frozen dataclasses)
│   ├── body.py          # BodyGraph (add/remove/validate/sample)
│   ├── builder.py       # YAML → BodyGraph with flow conservation check
│   └── presets.py       # reference_man(), reference_woman()
│
├── engine/              # ODE compilation and solving (identity-blind)
│   ├── compiler.py      # ODECompiler, CompiledODE, ResolvedParams
│   ├── flux.py          # FluxSpec implementations (5 transport types)
│   ├── solver.py        # LSODA wrapper (solve, solve_mc)
│   └── uncertainty.py   # Monte Carlo propagation
│
├── predict/             # SMILES → drug parameterization
│   ├── chemistry.py     # Molecular profiling, pKa, AD assessment
│   ├── adme.py          # XGBoost ADME property prediction
│   └── ivive.py         # In vitro → in vivo extrapolation, Kp
│
├── ml/                  # Data-driven PK prediction
│   ├── features.py      # Feature vector construction
│   ├── models.py        # XGBoost Cmax predictor
│   └── ensemble.py      # Meta-learner (PBPK + ML combination)
│
├── pk/                  # PK endpoint extraction
│   ├── endpoints.py     # SimResult → PKEndpoints
│   ├── nca.py           # Non-compartmental analysis (AUC, t½)
│   └── analytical.py    # Closed-form 1-cpt and 2-cpt solutions
│
├── regimen/             # Multi-dose and clinical pharmacology
│   ├── types.py         # DosingEvent, DosingRegimen (frozen dataclasses)
│   ├── solver.py        # Event-driven multi-dose solver
│   ├── profile.py       # Steady-state detection, Css metrics
│   ├── tdm.py           # Bayesian TDM via importance sampling
│   └── dosing.py        # MIPD dose recommendation
│
├── validation/          # Benchmarking infrastructure
│   ├── reference.py     # Clinical PK reference loader (290 drugs)
│   ├── benchmark.py     # Holdout benchmark runner
│   ├── metrics.py       # AAFE, fold error, PI coverage
│   └── split.py         # Scaffold-stratified splitting
│
└── pipeline/            # End-to-end orchestration
    ├── predict.py       # SMILES → PredictionResult
    └── config.py        # Pipeline configuration

data/
├── physiology/          # BodyGraph YAML definitions
├── compounds/           # Curated compound configurations
└── reference/           # Clinical PK reference data, holdout split

models/                  # Pre-trained XGBoost models (not in git)
```

## Predecessor

Sisyphus inherits validated data assets from [Omega PBPK](https://github.com/jam-sudo/Omega) (591 commits) but not its architecture:

| Inherited (data) | Not inherited (architecture) |
|-------------------|------------------------------|
| 290-drug clinical reference | 35-state hardcoded ODE system |
| Scaffold-stratified holdout split | Organ-specific CL<sub>int</sub> fields |
| ICRP physiology values | Sequential ADME &rarr; IVIVE chain |
| Pre-trained XGBoost models | Point-estimate pipeline |
| Rodgers &amp; Rowland tissue compositions | Post-hoc hybrid selector |

Key empirical findings from Omega that informed Sisyphus:

- **Data quality dominates model choice.** 14 reference corrections reduced AAFE by 47.5% with zero model changes.
- **Gut CL<sub>int</sub> &gt; hepatic CL<sub>int</sub> for C<sub>max</sub>.** Global sensitivity analysis (Sobol): gut S<sub>T</sub>=0.47, hepatic S<sub>T</sub>=0.00.
- **Meta-learner &gt; fixed ensemble.** Feature importance: ML C<sub>max</sub> 50%, PBPK C<sub>max</sub> 26%.

## References

- Berezhkovskiy, L. M. (2004). Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. *J Pharm Sci*, 93(6), 1628&ndash;1640.
- Houston, J. B. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. *Biochem Pharmacol*, 47(9), 1469&ndash;1479.
- Huang, K., et al. (2021). Therapeutics Data Commons: Machine learning datasets and tasks for drug discovery and development. *NeurIPS Datasets and Benchmarks*.
- ICRP (2002). Basic anatomical and physiological data for use in radiological protection: reference values. *ICRP Publication 89*.
- Obach, R. S., et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. *J Pharmacol Exp Ther*, 283(1), 46&ndash;58.
- Petzold, L. R. (1983). Automatic selection of methods for solving stiff and nonstiff systems of ordinary differential equations. *SIAM J Sci Stat Comput*, 4(1), 136&ndash;148.
- Poulin, P., &amp; Theil, F. P. (2002). Prediction of pharmacokinetics prior to in vivo studies. *J Pharm Sci*, 91(4), 940&ndash;951.
- Rodgers, T., &amp; Rowland, M. (2005). Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J Pharm Sci*, 95(6), 1238&ndash;1257.
- Rodgers, T., &amp; Rowland, M. (2006). Mechanistic approaches to volume of distribution predictions: Understanding the processes. *Pharm Res*, 24(5), 918&ndash;933.
- Shimada, T., et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. *J Pharmacol Exp Ther*, 270(1), 414&ndash;423.
- Yang, J., Jamei, M., Yeo, K. R., Tucker, G. T., &amp; Rostami-Hodjegan, A. (2007). Prediction of intestinal first-pass drug metabolism. *Curr Drug Metab*, 8(7), 676&ndash;684.
- Yu, L. X., &amp; Amidon, G. L. (1999). A compartmental absorption and transit model for estimating oral drug absorption. *Int J Pharm*, 186(2), 119&ndash;125.

## How to Cite

If you use Sisyphus in your research, please cite:

```
Yoon, J. M. (2026). Sisyphus (v1.0.0): Graph-based whole-body PBPK
simulation with native uncertainty propagation.
https://github.com/jam-sudo/Sisyphus
```

## Requirements

- Python &ge; 3.10
- numpy, scipy, pyyaml (core)
- rdkit, xgboost, scikit-learn (prediction)

## License

MIT
